ehave-logo.png
Ehave Provides Progress Update on its HPPD Study with University of Melbourne
February 02, 2023 08:30 ET | Ehave
MIAMI, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Ehave, Inc. (OTC Pink: EHVVF) (the "Company"), a Healthcare Analytics provider with interests in the psychedelic and mental health sectors, is pleased to...
ehave-logo.png
Ehave Files 6-K Disclosing Research Project Agreement
August 24, 2021 08:30 ET | Ehave
MIAMI, Aug. 24, 2021 (GLOBE NEWSWIRE) -- Ehave, Inc., (OTC Pink: EHVVF) (the “Company”), a provider of digital therapeutics delivering evidence-based therapeutic interventions to patients, announced...
ehave-logo.png
Ehave Partners with Globally Recognized University to Target Hallucinogen Persisting Perception Disorder (HPPD)
August 04, 2021 08:30 ET | Ehave
MIAMI, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Ehave, Inc. (OTC Pink: EHVVF) (the “Company”), a provider of digital therapeutics for the psychedelic and mental health sectors, today announced a...
ehave-logo.png
Hallucinogen Persisting Perception Disorder (HPPD) Research Initiated By Ehave
July 29, 2021 08:30 ET | Ehave
HPPD is a psychiatric disorder characterized by the persisting presence of sensory disturbances, most commonly visual, that resemble those produced by the use of hallucinogenic substances. Ehave...